

January 28, 2022

TO: Saskatchewan Health Authority
 Indigenous Services Canada- Saskatchewan Region
 Northern Intertribal Health Authority
 Saskatchewan Medical Association
 College of Registered Nurses of Saskatchewan
 Saskatchewan College of Pharmacy Professionals
 Saskatchewan College of Paramedics
 Saskatchewan College of Respiratory Therapists
 Saskatchewan Association of Licensed Practical Nurses
 College of Physicians and Surgeons of Saskatchewan
 Registered Psychiatric Nurses Association of Saskatchewan
 Drug Plan and Extended Benefits Branch

Re: Three Dose Primary Series of COVID-19 Vaccine in 5-11 Year Old Immunocompromised Population

Dear Colleagues:

The Government of Saskatchewan is providing information on the primary series for children 5- 11 years of age who are moderately to severely immunocompromised.

On January 25, 2022, the National Advisory Committee on Immunization (NACI) updated its recommendations on the use of COVID-19 vaccine in 5-11 age group (<https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccines-children-5-11-years-age.pdf>), and recommended a three dose primary series for children 5-11 years old with certain medical conditions that make them moderately to severely immunocompromised.

Effective **immediately** the following individuals who are 5-11 years of age who are moderately to severely immunocompromised should be offered a three dose primary series of the Pfizer BioNTech Comirnaty 5-11 years vaccine (10 mcg) using the recommended interval of 4 to 8 weeks between each dose (minimum interval of 21 days between doses one and two) as noted in **Table 1**.


Table 1: Eligible Populations

Population	Interval Between First and Second Dose	Interval Between Second and Third Dose
Children 5 to 11 years of age with the following conditions: <ul style="list-style-type: none"> Active treatment for solid tumour or hematologic malignancies Receipt of solid-organ transplant and taking immunosuppressive therapy 	4-8 weeks recommended (minimum interval -21 days)	4-8 weeks



<ul style="list-style-type: none"> • Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy) • Moderate to severe primary immunodeficiency with associated humoral and/or cell-mediated immunodeficiency or immune dysregulation • HIV with prior AIDS defining illness OR prior CD4 count \leq 200/mm³ OR prior CD4 fraction \leq 15% OR perinatally acquired HIV infection • Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the Canadian Immunization Guide for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive. 		
<p>Children 5 to 11 years of age who are moderately to severely immunocompromised as above, who have previously received two doses of the Pfizer BioNTech Comirnaty vaccine (10 mcg), should be offered a third dose of the Pfizer BioNTech Comirnaty vaccine (10 mcg) 4 to 8 weeks after the second dose.</p>	<p>N/A as completed</p>	<p>4-8 weeks</p>

Sincerely,



Dr. Saqib Shahab
 Chief Medical Health Officer